• Alias: MK-1775
    • Small-molecule WEE1 inhibitor that is a key regulator of cell cycle progression. WEE1 inhibits CDK1, which effects G2/M cell cycle checkpoint and therefore the regulation of cell size and DNA damage.
    • Phase 2 in combination with gemcitabine in recurrent ovarian, primary peritoneal, or fallopian tube cancer; phase 2 in combination with olaparib, AZD5363 (AKT-inhibitor), AZD2014 (mTOR inhibitor) in advanced solid tumors
    • Recommended dose: Intermittent dosing twice weekly to three times weekly with dose ranging from 200 to 325 mg with chemotherapy
    • Half-life: 7.6 to 12.2 hours
    • Common side effects:
    Other topics in Targeted and Immunotherapy Agents